Recombinant Anti-CCR7 antibody [Y59] - Low endotoxin, Azide free (ab221209)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y59] to CCR7 - Low endotoxin, Azide free
- Suitable for: WB, IP, ICC/IF, Mass Cytometry
- Reacts with: Human
Overview
-
Product name
Anti-CCR7 antibody [Y59] - Low endotoxin, Azide free
See all CCR7 primary antibodies -
Description
Rabbit monoclonal [Y59] to CCR7 - Low endotoxin, Azide free -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, ICC/IF, Mass Cytometrymore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Rhesus monkey -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: C6, Raw264.7, PC12 cell lysates. ICC/IF: Jurkat cells. IMC: Human tonsil tissue
-
General notes
ab221209 is the carrier-free version of ab32527.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.20
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y59 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Alexa Fluor® 488 Anti-CCR7 antibody [Y59] (ab196459)
- HRP Anti-CCR7 antibody [Y59] (ab196475)
- Alexa Fluor® 647 Anti-CCR7 antibody [Y59] (ab196640)
- Alexa Fluor® 594 Anti-CCR7 antibody [Y59] (ab207016)
- Alexa Fluor® 555 Anti-CCR7 antibody [Y59] (ab207018)
- Alexa Fluor® 568 Anti-CCR7 antibody [Y59] (ab207019)
- Anti-CCR7 antibody [Y59] (ab32527)
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab221209 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration.
|
|
IP |
Use at an assay dependent concentration.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
|
Mass Cytometry |
Use at an assay dependent concentration.
|
Notes |
---|
WB
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
Mass Cytometry
Use at an assay dependent concentration. |
Target
-
Function
Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions. -
Tissue specificity
Expressed in various lymphoid tissues and activated B- and T-lymphocytes, strongly up-regulated in B-cells infected with Epstein-Barr virus and T-cells infected with herpesvirus 6 or 7. -
Sequence similarities
Belongs to the G-protein coupled receptor 1 family. -
Cellular localization
Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 1236 Human
- Entrez Gene: 12775 Mouse
- Entrez Gene: 287673 Rat
- Omim: 600242 Human
- SwissProt: P32248 Human
- SwissProt: P47774 Mouse
- Unigene: 370036 Human
- Unigene: 2932 Mouse
-
Alternative names
- BLR 2 antibody
- BLR2 antibody
- C C chemokine receptor type 7 antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-CCR7 antibody [Y59] - Low endotoxin, Azide free (ab221209)
Immunocytochemistry/Immunofluorescence analysis of Jurkat (human T cell leukemia cell line from peripheral blood) cells labelling CCR7 with purified ab32527 at 1/100. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/500) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. ab7291, a mouse anti-tubulin (1/1000) and ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) were also used.
Control 1: primary antibody (1/100) and secondary antibody, ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/500).
Control 2: ab7291 (1/1000) and secondary antibody, ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/500).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32527).
-
ab32527 (purified) at 1/20 immunoprecipitating CCR7 in MCF7 (human breast adenocarcinoma cell line) whole cell lysate. 10 ug of cell lysate was present in the input. For western blotting, a HRP-conjugated Veriblot for IP Detection Reagent (ab131366) was used for detection at 1/10,000 dilution. A rabbit monoclonal IgG (ab172730) was used intead of ab128913 as a negative control (Lane 3).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32527).
Protocols
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (14)
ab221209 has been referenced in 14 publications.
- Qiao X et al. Magnesium-doped Nanostructured Titanium Surface Modulates Macrophage-mediated Inflammatory Response for Ameliorative Osseointegration. Int J Nanomedicine 15:7185-7198 (2020). PubMed: 33061375
- Shi JY et al. Naive Treg-like CCR7(+) mononuclear cells indicate unfavorable prognosis in hepatocellular carcinoma. Tumour Biol 37:9909-17 (2016). IF ; Human . PubMed: 26813566
- Zhang L et al. CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-?B Pathway. PLoS One 11:e0158529 (2016). PubMed: 27505247
- Pang MF et al. TGF-ß1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. Oncogene N/A:N/A (2015). WB, IHC-P, IF ; Mouse, Human . PubMed: 25961925
- Hayashi E et al. Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma. Hum Pathol 44:1927-36 (2013). PubMed: 23706909